MedPath

Retrospective study for investigation of proteinuria generation and anti-proteinuria effect of RAS inhibitor in non-small cell lung cancer patients who received bevacizumab chemotherapy(NJLCG1303)

Not Applicable
Recruiting
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000012403
Lead Sponsor
orth Japan Lung Cancer Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with diabetes during treatment

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proteinuria(1+ or severer dipstick and/or 0.15g/gCr or severer UPCR)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath